Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEC-89736
- Development stage
- Phase 1
- Lead developer
- Sunshine Lake Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HEC-89736 is an orally administered small molecule drug in development by Sunshine Lake Pharma, a subsidiary of HEC Pharm. It is being investigated for the treatment of relapsed or refractory B-cell hematologic malignancies, including chronic lymphocytic leukemia (CLL). The drug is currently in early clinical trials (Phase 1) to evaluate its safety, tolerability, and pharmacokinetics in patients with these conditions. The precise mechanism of action has not been publicly disclosed as of the latest available information[1][3][4][5].
- Other names
- HEC89736 p-toluenesulfonateHEC-89736 p-toluenesulfonateHEC 89736 p-toluenesulfonate
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on HEC-89736.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEC-89736.